Orchestra BioMed Holdings (OBIO) Interest & Investment Income (2023 - 2026)
Orchestra BioMed Holdings (OBIO) reported Interest & Investment Income of -$821000.0 for Q1 2026, down 594.58% year-over-year from $166000.0 in Q1 2025, and down 7.6% on a QoQ basis from -$763000.0 in Q4 2025.
Orchestra BioMed Holdings (OBIO) has 4 years of Interest & Investment Income data on file, last reported at -$821000.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 594.58% year-over-year to -$821000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.1 million (down 185.2% YoY) and the FY2025 annual result came in at -$1.1 million, down 134.21% from the prior year.
- Interest & Investment Income retreated to -$821000.0 in Q1 2026 per OBIO's latest filing, from -$763000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $1.1 million in Q4 2023 and bottomed at -$821000.0 in Q1 2026.
- The 4-year median for Interest & Investment Income is $522000.0 (2024), against an average of $310000.0.
- The widest annual swing landed in 2024, when Interest & Investment Income grew 0.11%; it then sank 594.58% in 2026.
- Tracing OBIO's Interest & Investment Income over 4 years: stood at $1.1 million in 2023, then tumbled by 52.89% to $522000.0 in 2024, then plunged by 246.17% to -$763000.0 in 2025, then slipped by 7.6% to -$821000.0 in 2026.
- Per Business Quant, the three latest OBIO Interest & Investment Income figures stand at -$821000.0 (Q1 2026), -$763000.0 (Q4 2025), and -$515000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Orchestra BioMed Holdings | 245.24 Mn | 255.02 Mn | 78,000.00 | -821,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -821,000.00 |
| Dec 31, 2025 | -763,000.00 |
| Sep 30, 2025 | -515,000.00 |
| Jun 30, 2025 | -36,000.00 |
| Mar 31, 2025 | 166,000.00 |
| Dec 31, 2024 | 522,000.00 |
| Sep 30, 2024 | 916,000.00 |
| Jun 30, 2024 | 902,000.00 |
| Mar 31, 2024 | 1.02 Mn |
| Dec 31, 2023 | 1.11 Mn |
| Sep 30, 2023 | 915,000.00 |